Simultaneous Quantification of Ramipril and Ramiprilat in Drug Formulations: A Clinical LC-MS/MS Study

Determination of Ramipril and Ramiprilat

  • Khaled Omari College of Engineering and Technology, American University of the Middle East, Kuwait https://orcid.org/0000-0002-3089-2893
  • Ahmed Abu-Awwad Faculty of Pharmacy, Jerash University, Amman –Jordan
  • Basel Arafat Faculty of Medical Sciences and Public Health, Anglia Ruskin University, Chelmsford, UK
  • Gianina Macovei Antibiotice S.A. 1, Valea Lupului, Iaşi, 707410, Romania
  • TLucretia Boltez Antibiotice S.A. 1, Valea Lupului, Iaşi, 707410, Romania
  • Zaher Abdel Baki College of Engineering and Technology, American University of the Middle East, Kuwait
  • Eyad Mallah Faculty of Pharmacy and Medical Sciences, University of Petra, Amman –Jordan
  • Tawfiq Arafat The Jordan Center for Pharmaceutical Research, Amman –Jordan
Keywords: chromatographic/spectrometric techniques, hypertension, metabolite, organic medicinal, pharmaceutical chemistry, pharmacokinetics.

Abstract

Ramipril is a drug controlling hypertension. Two drugs were studied in 36 healthy adults. The drugs are the test (Atb®) and the reference (Tritace®). This concept is crucial in the pharmaceutical industry during the development process. The maximum concentration (Cmax) of Ramipril and its metabolite (Ramiprilat) were determined throughout drug administration in healthy subjects. All analysis was performed using LC-MS/MS. The method was validated over a range of 0.200 – 25.000 ng/mL in which linearity (R2) was 0.9983, accuracy was 99.9%, precision (CV) was less than 20%, and the Lower Limit of Quantitation was 0.200 ng/mL. Stability and other parameters were discussed. The time needed to reach this concentration (Tmax) and the time-drug concentration area under the curve (AUC) were most agreed upon. The two drugs were proven to be interchangeable. Both have similar pharmacokinetics and bioequivalence profiles. Consequently, the drugs are bioequivalent and considered alternatives to one another pharmaceutically. For example, 90% confidence intervals (C.I.) for the in-tra-individual ratios (test/reference) for pharmacokinetic parameters were Cmax, and AUC0-t for total exposure C.I. Log – transformed Values were 80-125 %.

Author Biography

Khaled Omari, College of Engineering and Technology, American University of the Middle East, Kuwait

Please, type the affiliation exactly as per this page.

References

Dr. Tariq Massad
Vice President
Eurofins CDMO Alphora Inc.
Email: tariq.massad@bpt.eurofinsca.com
Published
2024-09-25
How to Cite
Omari, K., Abu-Awwad, A., Arafat, B., Macovei, G., Boltez, T., Abdel Baki, Z., Mallah, E., & Arafat, T. (2024). Simultaneous Quantification of Ramipril and Ramiprilat in Drug Formulations: A Clinical LC-MS/MS Study. Indonesian Journal of Pharmacy, 35(3), 512–520. https://doi.org/10.22146/ijp.9302
Section
Research Article